Evidence map›Paper›PMID 41194047›Full record

ArticleBMC cancer2025

Polymorphisms in DNA repair related genes as risk factors for lung cancer in Cuban population: a case control study.

Elizabeth Reyes-Reyes, Elizabeth Cuétara-Lugo, José Alfredo Herrera-Isidrón, Mario Pérez-Benítez, Idania González-Pérez, Marlen Izquierdo-González, Yoanna Ivette Flores-Vega, Diana Laura Páramo-González, Claudina Angela Pérez-Novo, Miguel David Fernández-Pérez and 2 more

Abstract read
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Elizabeth Reyes-ReyesDepartment of Pharmacology, Institute of Marine Sciences, Havana, Cuba.
Elizabeth Cuétara-LugoDepartment of Clinical and Experimental Pharmacology, Institute of Oncology and Radiobiology, Havana, Cuba.
José Alfredo Herrera-IsidrónInstitute of Materials Science and Technology, University of Havana, Havana, Cuba.
Mario Pérez-BenítezCuban Institute of Ophthalmology "Ramón Pando Ferrer", Havana, Cuba.
Idania González-PérezDepartment of Clinical and Experimental Pharmacology, Institute of Oncology and Radiobiology, Havana, Cuba.
Marlen Izquierdo-GonzálezDepartment of Pharmacology, Institute of Marine Sciences, Havana, Cuba.
Yoanna Ivette Flores-VegaDepartment of Medical Oncology, Institute of Oncology and Radiobiology, Havana, Cuba.
Diana Laura Páramo-GonzálezDepartment of Medical Oncology, Institute of Oncology and Radiobiology, Havana, Cuba.
Claudina Angela Pérez-NovoDepartment of Biomedical Sciences, Cell Death Signaling lab, Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium.
Miguel David Fernández-PérezDepartment of Pharmacology, Institute of Marine Sciences, Havana, Cuba.
Wim Vanden-BergheDepartment of Biomedical Sciences, Cell Death Signaling lab, Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium. wim.vanderberghe@uantwerpen.be.
Idania Rodeiro-GuerraDepartment of Pharmacology, Institute of Marine Sciences, Havana, Cuba. idania.rodeiro@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSingle nucleotide variants are important factors involved in lung cancer onset and prognosis. In Cuba, there are scarce studies evaluating the possible association between genetic variants and lung cancer. Here, we described the frequency distribution of genetic variants in DNA repair related genes and assessed their impact on lung cancer susceptibility and survival prognosis in a cohort of Cuban population

methodsCase-Control study included 300 lung cancer patients and 300 control subjects. Variants: rs1042522, rs11016879, rs13181, rs25487 and rs861539 were genotyped. The association analysis was evaluated by logistic regression and the impact on overall survival was estimated by Kaplan-Meier and Cox regression analyses.

resultsGenotype frequencies were in Hardy-Weinberg equilibrium except for rs1042522 in patients. The heterozygote of this variant was associated with low risk to lung cancer (Overdominant, OR: 0.53, p = 0.01). Conversely, rs25487 showed trend to additive genotype risk (Additive model, OR:1.61, p = 0.01). Differences in genotype frequencies according to skin color of controls were detected for rs1042522 and rs861539 (p = 0.01). The rs11016879 and rs1042522 showed joint protective effects with skin color. Interaction between rs25487 and cigarette smoking analysis revealed higher lung cancer risk (OR = 3.72, p = 0.03, p-interaction: 0.01). Interaction between alcohol consumption and rs13181 reached borderline significance for decreased risk of lung cancer (OR = 0.25, p = 0.03, p-interaction: 0.06). In addition, rs11016879 alternative allele was an independent factor for higher mean 5-years overall survival (log-rank test p = 0.03).

conclusionsThe study provides the first data evaluating the relevance of genetic variants in DNA damage repair related genes for lung cancer management in Cuban population. Our findings indicate a significant contribution of the genetic variants to lung cancer susceptibility and highlights the importance of considering skin color within analyses for disease susceptibility in Cuban population.

Indexed as

DNA RepairGenetic Predisposition to DiseaseLung NeoplasmsPolymorphism, Single NucleotideAdultAgedCase-Control StudiesCubaFemaleGenotypeHumansMaleMiddle AgedPrognosisRisk FactorsAdmixed populationDNA repairGenetic susceptibilityLung cancerSingle nucleotide variants

Identifiers

PMID41194047
PMCPMC12587590

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.